Anti-SARS-CoV-2 Nucleocapsid Antibody, Human IgG1 (AS95) (MALS verified)

Anti-SARS-CoV-2 Nucleocapsid Antibody, Human IgG1 is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from CHO cells. This monoclonal antibody is purified by Protein A affinity chromatography. As verified by binding test with N-NTD (Cat.No. NUN-C5143) and N-CTD (Cat.No. NUN-C5145) protein, this antibody can only bind to N-NTD (AA Gly 44 - Glu 174) . ELISA test validated that this antibody can bind multiple N protein variants with similar affinity as compared to the wild type N protein (Cat.No. NUN-C5227) .

Product Specifications

Background

Nucleocapsid (N) protein is the most abundant protein found in coronavirus. CoV N protein is a highly immunogenic phosphoprotein important for viral genome replication and modulation of cell signaling pathways. It was first identified by a research team while they were screening for ADP-ribosylated proteins during coronavirus (CoV) infection (Grunewald M. E., et al. 2017, Virology; 517: 62-68) . The array of diverse functional activities accommodated in N protein makes it more than a structural protein but also an interesting target in the development of antiviral therapeutics. Because of the conservation of N protein sequence and its strong immunogenicity, N protein of coronavirus is chosen as a diagnostic tool.

CAS Number

9007-83-4

Host

CHO

Origin Species

Human

Target

Nucleocapsid protein

Conjugation

Unconjugated

Tag

Human IgG1 | Human Kappa

Stability

For long term storage, the product is stable for up to 3 years at -70°C from date of receipt; For short term storage, the product is stable for up to 12 months at 2-8°C from date of receipt. Please avoid repeated freeze-thaw cycles.

Purity

0.95

Bioactivity

Immobilized Anti-SARS-CoV-2 Nucleocapsid Antibody, Human IgG1 (AS95) (Cat. No. NUN-CH14) at 1μg/mL (100μL/well) can bind SARS-CoV-2 Nucleocapsid protein, His Tag (B.1.1.529/Omicron) (Cat. No. NUN-C52Ht) with a linear range of 0.4-6 ng/mL (Routinely tested).